Neumora Therapeutics, Inc.
NMRA
$1.84
-$0.13-6.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.81M | 12.18M | 15.32M | 18.79M | 17.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.48M | 52.70M | 54.04M | 70.94M | 62.92M |
| Operating Income | -58.48M | -52.70M | -54.04M | -70.94M | -62.92M |
| Income Before Tax | -59.45M | -56.76M | -52.71M | -67.89M | -58.82M |
| Income Tax Expenses | 0.00 | -- | 25.00K | 105.00K | 0.00 |
| Earnings from Continuing Operations | -59.45M | -56.76M | -52.73M | -67.99M | -58.82M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.45M | -56.76M | -52.73M | -67.99M | -58.82M |
| EBIT | -58.48M | -52.70M | -54.04M | -70.94M | -62.92M |
| EBITDA | -58.47M | -52.68M | -54.02M | -70.78M | -62.77M |
| EPS Basic | -0.35 | -0.35 | -0.33 | -0.42 | -0.37 |
| Normalized Basic EPS | -0.22 | -0.20 | -0.20 | -0.26 | -0.23 |
| EPS Diluted | -0.35 | -0.35 | -0.33 | -0.42 | -0.37 |
| Normalized Diluted EPS | -0.22 | -0.20 | -0.20 | -0.26 | -0.23 |
| Average Basic Shares Outstanding | 168.52M | 161.84M | 161.69M | 161.45M | 160.98M |
| Average Diluted Shares Outstanding | 168.52M | 161.84M | 161.69M | 161.45M | 160.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |